The latest thinking on patient-centric structures and strategies
How are drug companies responding and adapting to the inexorable pull towards the patient-centric world? Patient centricity has been a buzz word for a couple of years now and it is high time we assessed the impact it is having on pharma. Patient-centric pharma: Advancing the New Business Model reveals how success can be achieved and provides food for thought on various ways to place patients firmly at the heart of your business and achieve commercially beneficial outcomes. Based on interviews with 10 experts at the cutting edge of the patient revolution, this report lifts the lid on this business-critical area.
The clock cannot be turned back on patient empowerment; but what can change is how pharma responds. For some, it has already proved to be an opportunity to differentiate and edge ahead. What is clear is that there is no single blueprint for success and that the evolving landscape continues to offer plenty of opportunities for competitive advantage. Some will inevitably be left behind as the world moves on. But for those that genuinely engage with patients, there is much to gain.
“One of the biggest challenges is the structure of pharmaceutical companies. They're looking through the lens of a brand trying to identify what its competitor's doing, rather than truly looking at it from the patient perspective. That's the challenge that needs to be overcome if pharma is really going to become patient centred.”
Richard Jones, The Earthworks
“People want to understand what it means for them in their day-to-day work. They may hear that the company is patient-centric but they think ‘I’m working in finance for example, and it doesn't mean anything for me’. So, companies need to make it real for people there, or in manufacturing for example.”
Dr Neil Croft, Kinapse
“It's important to recognise that patient engagement is critical and we need to incorporate it early in the development process and have it aligned across pharma functions.”
Dr Tehseen Salimi, AstraZeneca
Need more information? Contact a consultant for an executive summary and sample pages from the report.
How patient-centric is your business?
Our information rich society has created more informed and vocal end users which means that patients have taken their place at the table and can no longer be ignored. Payers are also demanding proof of outcomes, which can only come from patient interaction. How are drug companies responding and adapting to the inexorable pull towards a patient-centric world? And how can your business move further along the patient focus spectrum?
Patient-centric pharma: Advancing the New Business Model reveals how success can be achieved and provides food for thought on various ways to place patients firmly at the heart of your business and achieve commercially beneficial outcomes. Based on interviews with 10 experts at the cutting edge of the patient revolution, this report lifts the lid on this business-critical area.
The clock cannot be turned back on patient empowerment; but what can change is how pharma responds. For some, it has already proved to be an opportunity to differentiate and edge ahead. What is clear is that there is no single blueprint for success and that the evolving landscape continues to offer plenty of opportunities for competitive advantage. Some will inevitably be left behind as the world moves on. But for those that genuinely engage with patients, there is much to gain.
“One of the biggest challenges is the structure of pharmaceutical companies. They're looking through the lens of a brand trying to identify what its competitor's doing, rather than truly looking at it from the patient perspective. That's the challenge that needs to be overcome if pharma is really going to become patient centred.”
Richard Jones, The Earthworks
“People want to understand what it means for them in their day-to-day work. They may hear that the company is patient-centric but they think ‘I’m working in finance for example, and it doesn't mean anything for me’. So, companies need to make it real for people there, or in manufacturing for example.”
Dr Neil Croft, Kinapse
“It's important to recognise that patient engagement is critical and we need to incorporate it early in the development process and have it aligned across pharma functions.”
Dr Tehseen Salimi, AstraZeneca
All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved